tiprankstipranks
Ovid Therapeutics Announces Leadership Transition and Consulting Deal
Company Announcements

Ovid Therapeutics Announces Leadership Transition and Consulting Deal

Don't Miss our Black Friday Offers:

The latest announcement is out from Ovid Therapeutics (OVID).

Ovid Therapeutics Inc. has announced that Thomas Perone, previously serving as General Counsel, Chief Compliance Officer and Corporate Secretary, will be departing the company due to workforce reduction but will remain as a consultant until January 2025. Under the new Consulting Agreement, Perone will be paid up to $55,000 and his equity awards will continue to vest through the consulting term, alongside agreeing to certain post-termination restrictions including non-solicitation.

Find detailed analytics on OVID stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyOvid Therapeutics reports Q3 EPS (20c), consensus (20c)
TheFlyOvid Therapeutics presents study results on OV329
TipRanks Auto-Generated NewsdeskOvid Therapeutics Elevates Meg Alexander to President and COO
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App